Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 18th Preview)
-
FDA regulatory flexibility for gene therapy filings
The FDA has reversed course on UniQure’s Huntington’s disease gene therapy, clearing the company to pursue an accelerated approval filing for AMT-130. UniQure said the agency accepted that a three-year analysis from an earlier phase I/II study is “acceptable” to support a marketing application, after previously requiring more data. UniQure now plans to submit its BLA in the third quarter, framing the decision as a regained willingness to use existing clinical datasets for accelerated pathways. The update follows earlier FDA skepticism tied to external-control evidence, which had constrained sponsors seeking approval. Separate reporting notes that UniQure and FDA aligned on a confirmatory trial design that may avoid a sham-controlled element, following a recent Type B meeting. Markets reacted positively, with UniQure shares jumping more than 70% in morning trading after the disclosure. For the gene therapy sector, the decision is another signal that FDA review posture—particularly around evidence standards for rare disease accelerated approvals—may be shifting toward greater flexibility, potentially changing timelines for other Huntington’s and rare neuro programs.
-
Biogen expands immunology with RayThera deal
Biogen struck a deal to buy RayThera for up to $1 billion, aiming to add a portfolio of early immunology assets to its pipeline. The acquisition is structured with an undisclosed upfront payment and backloaded milestone payments tied to clinical and regulatory progress. RayThera, a secretive startup founded in 2023, has publicly referenced anti-inflammatory drug candidates but provided limited detail on specific targets. The deal reflects Biogen’s effort to widen beyond its neurology focus, especially as the company integrates other recent acquisitions, including the $5.6 billion purchase of Apellis. Industry observers noted RayThera’s prior funding—an April 2025 Series A led by Foresite Capital and OrbiMed Advisors—positioned the company to advance programs quickly despite limited public disclosure. The purchase also highlights a continued appetite for immunology exposure where target biology and safety profiles remain central to differentiation. For immunology-focused investors and partners, the backloaded structure underscores how Biogen is treating these assets as optionality—paying most as clinical milestones are reached.
-
IBD pipeline financing and oral PDE4B strategy
cAMPfield Therapeutics raised a $180 million Series A to develop prifemilast, an oral PDE4B-selective therapy for inflammatory bowel disease. The company said the program is intended as an alternative to potent biologics such as Humira and Entyvio, targeting patients who do not achieve deep remission or who discontinue current therapies. Prifemilast traces back to vTv Therapeutics, which licensed the compound to Newsoara Biopharma for multiple Asian markets and later expanded rights. cAMPfield now holds rights outside of China and highlighted PDE4B selectivity—seeking efficacy while reducing dose-limiting adverse effects associated with PDE4D. cAMPfield’s leadership includes executives and veterans associated with prior IBD and GI development and commercialization, including experience tied to Entyvio, Otezla, Zeposia, and Humira. The company said early data in psoriasis showed robust efficacy with treatment discontinuation rates comparable to placebo. The round reinforces investor focus on oral small molecules for IBD, particularly mechanisms that can maintain anti-inflammatory potency without the tolerability challenges historically seen in PDE4 programs.
-
Clinical setbacks in oncology: Zynlonta faces safety signal in Phase 3
ADC Therapeutics reported a stumbling block for Zynlonta (loncastuximab tesirine) after Phase 3 results from LOTIS-5 showed higher fatal adverse events in the treatment arm. The antibody-drug conjugate combined with rituximab met the primary endpoint for progression-free survival versus rituximab alone, but overall deaths and Grade 5 treatment-emergent adverse events were elevated. ADC said overall survival did not show a detrimental effect on its key secondary efficacy endpoint, and it attributed part of the observed death-rate pattern to differences in observation windows and subsequent therapy switching. Still, infections were the leading cause of deaths and were higher in the test arm than in the control. Investors pointed to the magnitude of the Grade 5 TEAE imbalance versus the company’s earlier Phase 2 LOTIS-2 study, raising questions about risk management and future trial strategy. For the ADC space, the report is a reminder that confirmatory programs can expose safety liabilities even when efficacy endpoints are achieved, and that comparative mortality effects can reshape regulatory and commercial trajectories.
-
FDA extends comment window for AI-powered real-time clinical trials pilot
The FDA extended the comment period for its AI-powered real-time clinical trial (RTCT) pilot, giving sponsors and CROs more time to respond to how AI should be used to report endpoint data as studies progress. The agency pushed the deadline to June 29 in a Federal Register notice. The pilot is designed to explore whether real-time reporting—potentially using AI technologies—can improve trial efficiency, safety signal monitoring, dose selection, and early go/no-go decisions. The FDA previously cited examples from trials involving AstraZeneca and Amgen. In earlier remarks, FDA leadership framed the approach as a way for regulators to view safety signals and endpoints during trials instead of relying solely on end-of-study data. Analysts and legal observers said the extension provides additional opportunity for the pharma ecosystem to shape FDA’s evolving position on AI usage in regulatory decision-making across early-phase development.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.